The Value of RenalTech.

What is the value of being able to predict whether or not a cat will develop chronic kidney disease (CKD) prior to diagnosis? It is estimated that one in three cats will develop CKD over the course of their lifetime. The ability to predict which cats specifically is not just valuable to your patients and clients, but also to your bottom line.

Renaltech™ uses the computing power of artificial intelligence and machine learning to predict whether or not a cat will develop chronic kidney disease (CKD) up to 2 years prior to diagnosis with greater than 95% accuracy. This predictive tool was developed in collaboration with Mars Petcare and the Royal Veterinary College where over 150,000 medical records of feline patients were investigated.

In a one-year retrospective analysis of 730,000 feline patients that visited small animal clinics, RenalTech was a significant driver of increased visits, CKD-related food purchases, and CKD-related medications. 31.5% of cats receiving a RenalTech positive status purchased CKD-related food vs. only 4.8% percent of all other cats. Likewise, nearly 41% of RenalTech positive cats purchased CKD-related medications vs. only 26.3% of all other cats.

RenalTech impacts veterinarian visits and CKD-related purchases.

	AVERAGE VISITS	PURCHASING CKD FOOD	PURCHASING CKD-RELATED MEDS	PURCHASING BLOOD PRESSURE MEDS
No diagnostics performed	2.0	0.7%	5.5%	0.1%
Diagnostics without RenalTech	3.11	4.8%	26.3%	0.6%
Diagnostics with RenalTech	6.21	17.1%	31.1%	2.8%
RenalTech = Negative	4.62	1.4%	19.2%	0.3%
RenalTech = Inconclusive	5.27	3.8%	23.8%	0.8%
RenalTech = Positive	7.49	31.5%	40.7%	5.0%

CKD-related food and medication purchases increased by 8x and 2x respectively.

- No diagnostics performed
- Diagnostics without RenalTech
- Diagnostics with RenalTech

Declining feline patient visits have been an issue plaguing veterinary medicine for years, but we may be able to test our way out of this problem. RenalTech helps solves this problem by increasing feline visits by as much as 31%.

The data show the impact of RenalTech testing on the feline patient population. Regardless of the result, patient visits increased with RenalTech. For cats with a negative RenalTech results, visits increased 14% year-over-year, while those with positive results saw an astonishing 31% increase in patient visits.

RENALTECH RESULTS	PRE-RENALTECH LAUNCH	RENALTECH LAUNCH	VISIT INCREASE
	AVERAGE VISITS	AVERAGE VISITS	
RenalTech = Negative	4.1	4.67	14%
RenalTech = Inconclusive	4.35	5.36	23%
RenalTech = Positive	5.91	7.74	31%

Early detection of CKD through diagnostic testing helps veterinarians practice better medicine and also inspires improved care of their patients through diligent patient monitoring and personalized treatment plans. A RenalTech status provides veterinarians the opportunity to better educate cat owners about CKD, monitor these patients for signs and symptoms of CKD, and provide specific treatments as indicated throughout the course of CKD.

Predictive diagnostics like RenalTech offer veterinarians a better way to provide care to their patients. Antech is shifting the diagnostic paradigm by moving away from strictly relying on diagnosis and introducing the prediction of disease. Veterinarians will have the ability to intervene before disease strikes and ensure their patient are in optimal condition to face the disease, potentially even delaying onset. This will allow for the development of personalized care plans—an important step for the veterinary industry.

Learn how RenalTech can help grow feline visits, diagnostics, and purchases at your practice

VISIT **q-r.to/renaltech-grow**

Learn more about RenalTech and how to predict chronic kidney disease two years before it occurs

VISIT **q-r.to/renaltech**